Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses.

MLA

Mehra, Niven, et al. “Talazoparib, a Poly(ADP-Ribose) Polymerase Inhibitor, for Metastatic Castration-Resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses.” The Oncologist, vol. 27, no. 10, Oct. 2022, pp. e783–95. EBSCOhost, https://doi.org/10.1093/oncolo/oyac172.

APA

Mehra, N., Fizazi, K., de Bono, J. S., Barthélémy, P., Dorff, T., Stirling, A., Machiels, J.-P., Bimbatti, D., Kilari, D., Dumez, H., Buttigliero, C., van Oort, I. M., Castro, E., Chen, H.-C., Di Santo, N., DeAnnuntis, L., Healy, C. G., & Scagliotti, G. V. (2022). Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses. The Oncologist, 27(10), e783–e795. https://doi.org/10.1093/oncolo/oyac172

Chicago

Mehra, Niven, Karim Fizazi, Johann S de Bono, Philippe Barthélémy, Tanya Dorff, Adam Stirling, Jean-Pascal Machiels, et al. 2022. “Talazoparib, a Poly(ADP-Ribose) Polymerase Inhibitor, for Metastatic Castration-Resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses.” The Oncologist 27 (10): e783–95. doi:10.1093/oncolo/oyac172.